NCT04300998Recruiting
Study of CAR-T Therapy in Older Patients
Observational Study of Commercial Chimeric Antigen Receptor T-cell (CAR T) Therapy in Older Patients With Hematologic Malignancies and With an Embedded Pilot Study of Longitudinal Geriatric and Neurocognitive Evaluation
Source: ClinicalTrials.gov · Last updated 7 Apr 2026
Brief summary (registry, in English)
This study is being done to find out how older patients respond to CAR-T cell therapy and how the treatment affects their quality of life. This is a quality of life study and participating in the study does not involve receiving any treatment, other than the standard treatment for participants' disease.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 154 (estimated)
- First submitted
- 5 Mar 2020
- Start date
- 4 Mar 2020
- Primary completion date
- 4 Mar 2027
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Diseases
- Multiple myeloma
- NCT number
- NCT04300998
What you commit to
- Study type: Observational
- Planned participants: 154
- From 4 Mar 2020 to the primary completion date, 4 Mar 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Any prior commercial or investigational CAR T therapy (all cohorts)
Other illness
- Current diagnosis of major Axis I psychiatric disorder (DSM-IV), major depression, bipolar disorder, or schizophrenia, as per medical records or patient report (cohort 1 only)
- History of a neurological disorder, neurodegenerative disease, or traumatic brain injury with loss of consciousness (\>60 minutes), as per medical records or patient report (cohort 1 only)
- Current ongoing substance abuse and/or history of substance abuse, as per medical records or patient report (cohort 1 only)
- History of CNS disease (cohort 4 only)
Who the study is looking for
- are ≥60 years old (all cohorts)
- have pathologically confirmed, relapsed refractory lymphoid malignancy or plasma cell disorder receiving a commercial CAR T-cell product (all cohorts)
- able to speak and understand English (cohort 1 and 4 only)
- have a MoCA score of less than 26 out of 30 during the GA visit by a geriatrician prior to CAR T-cell treatment (cohort 4 only)
Age in the registry: 60 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Memorial Sloan-Kettering Cancer Center Coordinator of this site? Confirm its status | New York | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.